Carbohydrate side chains of Rauscher leukemia virus envelope glycoproteins are not required to elicit a neutralizing antibody response
- PMID: 2416953
- PMCID: PMC252732
- DOI: 10.1128/JVI.57.1.340-342.1986
Carbohydrate side chains of Rauscher leukemia virus envelope glycoproteins are not required to elicit a neutralizing antibody response
Abstract
Antisera raised against Rauscher leukemia virus (R-MuLV) contain a preponderance of antibodies against glycoprotein gp70 that are dependent on the presence of carbohydrate side chains for reactivity, as judged by immunoprecipitation or Western blotting. However, the majority of neutralizing antibodies were not dependent on the presence of carbohydrate, as indicated by (i) the ability of deglycosylated R-MuLV to adsorb neutralizing antibody from sera as efficiently as glycosylated R-MuLV and (ii) the ability of deglycosylated R-MuLV to induce neutralizing antibody responses when injected into rabbits. Moreover, a faster response was obtained with deglycosylated R-MuLV than with untreated control virus in the latter experiments. The results indicate that the neutralizing antibodies are a discrete subpopulation of the total antibody response. Furthermore, the carbohydrate moieties appear to afford protection to the virion during infection, rather than serve as a target for neutralization.
Similar articles
-
Carbohydrate dramatically influences immune reactivity of antisera to viral glycoprotein antigens.Science. 1984 Dec 14;226(4680):1328-30. doi: 10.1126/science.6505693. Science. 1984. PMID: 6505693
-
Natural immunity in mice to the envelope glycoprotein of endogenous ecotropic type C viruses: neutralization of virus infectivity.J Virol. 1977 Mar;21(3):974-80. doi: 10.1128/JVI.21.3.974-980.1977. J Virol. 1977. PMID: 191656 Free PMC article.
-
Purification and serological characterization of the major envelope glycoprotein from AKR murine leukemia virus and its reactivity with autogenous immune sera from mice.J Virol. 1976 Mar;17(3):727-36. doi: 10.1128/JVI.17.3.727-736.1976. J Virol. 1976. PMID: 56459 Free PMC article.
-
Current status and strategies for vaccines against diseases induced by human T-cell lymphotropic retroviruses (HTLV-I, -II, -III).Cancer Res. 1985 Sep;45(9 Suppl):4694s-4699s. Cancer Res. 1985. PMID: 2410115 Review.
-
GP4-specific neutralizing antibodies might be a driving force in PRRSV evolution.Virus Res. 2010 Dec;154(1-2):104-13. doi: 10.1016/j.virusres.2010.08.026. Epub 2010 Sep 15. Virus Res. 2010. PMID: 20837070 Review.
Cited by
-
A comparison of T cell responses to glycoprotein B (gB-1) of herpes simplex virus type 1 and its non-glycosylated precursor protein, pgB-1.Clin Exp Immunol. 1991 Oct;86(1):30-6. doi: 10.1111/j.1365-2249.1991.tb05769.x. Clin Exp Immunol. 1991. PMID: 1655317 Free PMC article.
-
Topological and operational delineation of antigenic sites on the HN glycoprotein of Newcastle disease virus and their structural requirements.J Virol. 1986 Dec;60(3):987-93. doi: 10.1128/JVI.60.3.987-993.1986. J Virol. 1986. PMID: 2431164 Free PMC article.
-
Localization of neutralizing regions of the envelope gene of feline leukemia virus by using anti-synthetic peptide antibodies.J Virol. 1987 Jan;61(1):8-15. doi: 10.1128/JVI.61.1.8-15.1987. J Virol. 1987. PMID: 2431166 Free PMC article.
-
Carbohydrates as antigenic determinants of glycoproteins.Biochem J. 1987 Jul 1;245(1):1-11. doi: 10.1042/bj2450001. Biochem J. 1987. PMID: 2444214 Free PMC article. Review. No abstract available.
-
Specificity of antibodies produced against native or desialylated human immunodeficiency virus type 1 recombinant gp160.J Virol. 1993 Mar;67(3):1693-7. doi: 10.1128/JVI.67.3.1693-1697.1993. J Virol. 1993. PMID: 7679751 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources